H<sub>1</sub> receptor | Histamine receptors | IUPHAR/BPS Guide to PHARMACOLOGY

H1 receptor

Target id: 262

Nomenclature: H1 receptor

Family: Histamine receptors

Annotation status:  image of a green circle Annotated and expert reviewed. Please contact us if you can help with updates.  » Email us

   GtoImmuPdb view: OFF :     H1 receptor has curated GtoImmuPdb data

Gene and Protein Information
class A G protein-coupled receptor
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human 7 487 3p25 HRH1 histamine receptor H1 14-15,23,46,65
Mouse 7 488 6 E3 Hrh1 histamine receptor H1 35
Rat 7 486 4q42 Hrh1 histamine receptor H 1 21
Previous and Unofficial Names
H1R | HH1R | Hisr
Database Links
Specialist databases
GPCRDB hrh1_human (Hs), hrh1_mouse (Mm), hrh1_rat (Rn)
Other databases
ChEMBL Target
DrugBank Target
Ensembl Gene
Entrez Gene
Human Protein Atlas
KEGG Gene
OMIM
RefSeq Nucleotide
RefSeq Protein
SynPHARM
UniProtKB
Wikipedia
Selected 3D Structures
Image of receptor 3D structure from RCSB PDB
Description:  Histamine H1 receptor in complex with antagonist
PDB Id:  3RZE
Ligand:  doxepin
Resolution:  3.1Å
Species:  Human
References:  79
Natural/Endogenous Ligands
histamine

Download all structure-activity data for this target as a CSV file

Agonists
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Affinity Units Reference
dimethylhistaprodifen Hs Full agonist 6.4 pKi 78
pKi 6.4 [78]
methylhistaprodifen Hs Full agonist 6.4 pKi 78
pKi 6.4 (Ki 3.98x10-7 M) [78]
ST-1006 Hs Agonist <6.0 pKi 71
pKi <6.0 (Ki >1x10-6 M) [71]
2-(3-iodophenyl)histamine Hs Full agonist 5.8 pKi 78
pKi 5.8 [78]
2-(3-bromophenyl)histamine Hs Full agonist 5.7 pKi 78
pKi 5.7 [78]
2-(3-chlorophenyl)histamine Hs Full agonist 5.7 pKi 78
pKi 5.7 [78]
histaprodifen Hs Full agonist 5.7 pKi 49
pKi 5.7 [49]
2-(2-thiazolyl)ethanamine Hs Partial agonist 5.3 pKi 78
pKi 5.3 [78]
histamine Hs Full agonist 4.7 – 5.9 pKi 7,65,74,78,87
pKi 4.7 – 5.9 [7,65,74,78,87]
UR-PG55B Hs Full agonist 5.2 pKi 87
pKi 5.2 [87]
UR-PG131A Hs Full agonist 4.7 pKi 87
pKi 4.7 [87]
UR-PG153 Hs Full agonist 4.7 pKi 87
pKi 4.7 [87]
oxo-arpromidine Hs Full agonist 4.5 pKi 87
pKi 4.5 [87]
UR-PG146 Hs Full agonist 4.4 pKi 87
pKi 4.4 [87]
2-pyridylethylamine Hs Full agonist 3.7 pKi 74
pKi 3.7 [74]
vilazodone Hs Agonist 6.5 pIC50 31
pIC50 6.5 (IC50 3.17x10-7 M) [31]
Antagonists
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Affinity Units Reference
[11C]doxepin Hs Antagonist 9.0 pKd 37
pKd 9.0 (Kd 1x10-9 M) [37]
[3H]pyrilamine Hs Inverse agonist 8.4 – 9.1 pKd 15,65,77-78
pKd 8.4 – 9.1 (Kd 4x10-9 – 7.9x10-10 M) [15,65,77-78]
tripelennamine Hs Antagonist 8.0 pKd 30
pKd 8.0 (Kd 1x10-8 M) [30]
clemastine Hs Antagonist 10.3 pKi 3
pKi 10.3 (Ki 4.9x10-11 M) [3]
cyproheptadine Hs Antagonist 10.2 pKi 65
pKi 10.2 [65]
asenapine Hs Antagonist 9.8 pKi 77
pKi 9.8 [77]
doxepin Hs Antagonist 9.5 – 10.0 pKi 7
pKi 9.5 – 10.0 [7]
promethazine Hs Antagonist 9.6 pKi 25
pKi 9.6 (Ki 2.4x10-10 M) [25]
amitriptyline Hs Antagonist 9.3 pKi 25
pKi 9.3 (Ki 5x10-10 M) [25]
Description: Antagonism of [3H]mepyramine binding
clozapine Hs Antagonist 8.8 – 9.6 pKi 7,43,77
pKi 8.8 – 9.6 [7,43,77]
zotepine Hs Antagonist 9.2 pKi 77
pKi 9.2 [77]
alimemazine Bt Antagonist 9.1 pKi 44
pKi 9.1 (Ki 7.2x10-10 M) [44]
Description: Inhibition of [3H]mepyramine binding to bovine brain membrane preparations in vitro.
desloratadine Hs Antagonist 9.0 pKi 47
pKi 9.0 (Ki 9.7x10-10 M) [47]
olanzapine Hs Antagonist 8.7 – 9.2 pKi 43,77
pKi 8.7 – 9.2 [43,77]
azelastine Hs Antagonist 8.9 pKi 73
pKi 8.9 (Ki 1.26x10-9 M) [73]
pyrilamine Hs Inverse agonist 8.7 – 9.0 pKi 7,74
pKi 8.7 – 9.0 [7,74]
triprolidine Hs Antagonist 8.5 – 9.0 pKi 7,65
pKi 8.5 – 9.0 (Ki 3.16x10-9 – 1x10-9 M) [7,65]
(-)-trans-H2-PAT Hs Antagonist 8.6 – 8.8 pKi 7
pKi 8.6 – 8.8 [7]
hydroxyzine Hs Antagonist 8.7 pKi 27
pKi 8.7 (Ki 1.99x10-9 M) [27]
ketotifen Hs Antagonist 8.6 pKi 45
pKi 8.6 (Ki 2.5x10-9 M) [45]
astemizole Hs Antagonist 8.5 pKi 72
pKi 8.5 (Ki 3x10-9 M) [72]
(±)-trans-H2-PAT Hs Antagonist 8.4 – 8.6 pKi 7
pKi 8.4 – 8.6 [7]
(R)-cetirizine Hs Inverse agonist 8.5 pKi 74
pKi 8.5 [74]
(+)-chlorpheniramine Hs Antagonist 8.3 – 8.6 pKi 7,65
pKi 8.3 – 8.6 [7,65]
thiothixene Hs Antagonist 8.4 pKi 43
pKi 8.4 [43]
dosulepin Hs Antagonist 8.4 pKi 81
pKi 8.4 (Ki 4x10-9 M) [81]
quetiapine Hs Antagonist 8.0 – 8.7 pKi 43,77
pKi 8.0 – 8.7 [43,77]
cyclizine Hs Antagonist 8.4 pKi 3
pKi 8.4 (Ki 4.44x10-9 M) [3]
chlorpromazine Hs Antagonist 8.2 pKi 43
pKi 8.2 [43]
loxapine Hs Antagonist 8.2 pKi 43
pKi 8.2 [43]
cetirizine Hs Inverse agonist 8.2 pKi 65
pKi 8.2 [65]
chlorpheniramine Hs Antagonist 8.1 pKi 73
pKi 8.1 (Ki 7x10-9 M) [73]
perphenazine Hs Antagonist 8.1 pKi 43
pKi 8.1 [43]
(±)-cis-H2-PAT Hs Antagonist 7.8 – 8.2 pKi 7
pKi 8.1 – 8.2 [7]
pKi 7.8 – 7.9 [7]
fluspirilene Hs Antagonist 7.9 pKi 77
pKi 7.9 [77]
diphenhydramine Hs Antagonist 7.9 pKi 7
pKi 7.9 [7]
risperidone Hs Antagonist 7.6 – 7.8 pKi 43,77
pKi 7.6 – 7.8 [43,77]
thioridazine Hs Antagonist 7.7 pKi 43
pKi 7.7 [43]
fluphenazine Hs Antagonist 7.7 pKi 43
pKi 7.7 [43]
ziprasidone Hs Antagonist 7.4 – 7.8 pKi 43,77
pKi 7.4 – 7.8 [43,77]
fexofenadine Hs Antagonist 7.6 pKi 2
pKi 7.6 (Ki 2.7x10-8 M) [2]
aripiprazole Hs Antagonist 7.5 pKi 43
pKi 7.5 [43]
9-OH-risperidone Hs Antagonist 7.5 pKi 77
pKi 7.5 [77]
AZD3778 Hs Antagonist 7.5 pKi 5
pKi 7.5 (Ki 3.16x10-8 M) [5]
Description: Assayed using the sodium salt of the compound
(+)-trans-H2-PAT Hs Antagonist 7.4 – 7.5 pKi 7
pKi 7.4 – 7.5 [7]
loratadine Hs Antagonist 7.4 pKi 40
pKi 7.4 (Ki 3.7x10-8 M) [40]
terfenadine Hs Antagonist 7.4 pKi 2
pKi 7.4 (Ki 4x10-8 M) [2]
trifluoperazine Hs Antagonist 7.2 pKi 43
pKi 7.2 [43]
sertindole Hs Antagonist 6.9 pKi 43,77
pKi 6.9 [43,77]
(+)-cis-H2-PAT Hs Antagonist 6.9 pKi 7
pKi 6.9 [7]
(S)-cetirizine Hs Inverse agonist 6.7 pKi 74
pKi 6.7 [74]
BU-E 47 Hs Antagonist 6.6 pKi 78
pKi 6.6 [78]
(-)-chlorpheniramine Hs Antagonist 6.4 – 6.7 pKi 7
pKi 6.4 – 6.7 [7]
arpromidine Hs Antagonist 6.5 pKi 78,87
pKi 6.5 [78,87]
pimozide Hs Antagonist 6.2 pKi 43
pKi 6.2 [43]
JNJ-39758979 Hs Antagonist <6.0 pKi 71
pKi <6.0 (Ki >1x10-6 M) [71]
haloperidol Hs Antagonist 5.7 – 6.1 pKi 43,77
pKi 5.7 – 6.1 [43,77]
ABT-239 Hs Inverse agonist 5.8 pKi 19
pKi 5.8 [19]
pitolisant Hs Antagonist 5.8 pKi 71
pKi 5.8 [71]
molindone Hs Antagonist 5.7 pKi 43
pKi 5.7 [43]
pipamperone Hs Antagonist 5.6 pKi 77
pKi 5.6 [77]
A-349821 Hs Inverse agonist 5.6 pKi 18
pKi 5.6 [18]
clobenpropit Hs Antagonist 5.6 pKi 20
pKi 5.6 [20]
A-317920 Hs Antagonist 5.4 pKi 18,20
pKi 5.4 [18,20]
impromidine Hs Antagonist 5.2 pKi 87
pKi 5.2 [87]
ciproxifan Hs Antagonist <5.0 pKi 71
pKi <5.0 (Ki >1x10-5 M) [71]
MK-0249 Hs Antagonist <5.0 pKi 71
pKi <5.0 (Ki >1x10-5 M) [71]
conessine Hs Antagonist <5.0 pKi 71
pKi <5.0 (Ki >1x10-5 M) [71]
INCB-38579 Hs Antagonist <5.0 pKi 71
pKi <5.0 (Ki >1x10-5 M) [71]
epinastine Hs Antagonist 7.6 pIC50 33
pIC50 7.6 (IC50 2.5x10-8 M) [33]
Description: Antagonism of 5 nM [3H]mepyramine binding in an intact cell assay using U373 MG astrocytoma cells.
tripelennamine Hs Antagonist 7.4 pIC50 30
pIC50 7.4 (IC50 3.98x10-8 M) [30]
[11C]pyrilamine Hs Inverse agonist - -
View species-specific antagonist tables
Antagonist Comments
Astemizole is highly selective for the histamine H1 receptor over the H2 receptor.
Immunopharmacology Comments
The H1 receptor was the first of the family to be targeted for clinical use, with antagonists (anti-histamines) developed that are still used widely to treat alleric inflammation such as rhinitis, allergic conjunctivitis, urticaria and even anaphylaxis.
Cell Type Associations
Immuno Cell Type:  Granulocytes
Cell Ontology Term:   eosinophil (CL:0000771)
Comment:  Eosinophils express all four histamine receptor subtypes.
References:  26,60
Immuno Cell Type:  Mast cells
Cell Ontology Term:   mast cell (CL:0000097)
Comment:  In humans, mast cells express H1R, H2R and H4R.
References:  24
Immuno Process Associations
Immuno Process:  Inflammation
GO Annotations:  Associated to 2 GO processes
GO:0006954 inflammatory response TAS
click arrow to show/hide IEA associations
GO:0048245 eosinophil chemotaxis IEA
Immuno Process:  Chemotaxis & migration
GO Annotations:  Associated to 1 GO processes, IEA only
click arrow to show/hide IEA associations
GO:0048245 eosinophil chemotaxis IEA
Primary Transduction Mechanisms
Transducer Effector/Response
Gq/G11 family Adenylate cyclase stimulation
Comments:  Stimulation of cAMP accumulation is via Gβγ subunits of Gq [55].
References:  55
Secondary Transduction Mechanisms
Transducer Effector/Response
Gq/G11 family Phospholipase C stimulation
References:  48
Tissue Distribution
Brain: cerebrum.
Heart: myocardium (ventricle > atrium).
Species:  Human
Technique:  Northern and Western blotting.
References:  59
Brain.
Species:  Human
Technique:  Positron emission tomography (PET).
References:  64
Cranial arteries.
Species:  Human
Technique:  RT-PCR.
References:  39
Myometrium.
Species:  Human
Technique:  Radioligand binding.
References:  28
Gastrointestinal tract.
Species:  Human
Technique:  qRT-PCR and immunohistochemistry.
References:  75
Uterine horns.
Species:  Mouse
Technique:  Radioligand binding.
References:  29
Mast cells.
Species:  Mouse
Technique:  RT-PCR.
References:  34
Sympathetic preganglionic neurons in the spinal cord.
Species:  Rat
Technique:  RT-PCR.
References:  85
Embryonic brain and spinal cord.
Species:  Rat
Technique:  in situ hybridization, RT-PCR and Northern blotting.
References:  42
Brain: cerebrum.
Heart: myocardium (atrium and ventricle).
Species:  Rat
Technique:  Northern and Western blotting.
References:  59
Cochlea.
Species:  Rat
Technique:  RT-PCR.
References:  4
Expression Datasets

Show »

Log average relative transcript abundance in mouse tissues measured by qPCR from Regard, J.B., Sato, I.T., and Coughlin, S.R. (2008). Anatomical profiling of G protein-coupled receptor expression. Cell, 135(3): 561-71. [PMID:18984166] [Raw data: website]

There should be a chart of expression data here, you may need to enable JavaScript!
Functional Assays
Measurement of IP levels in COS-7 cells transfected with the human H1 receptor.
Species:  Human
Tissue:  COS-7 cells.
Response measured:  Stimulation of IP formation.
References:  14
Measurement of IP levels in CHO cells transfected with the human H1 receptor.
Species:  Human
Tissue:  CHO cells.
Response measured:  Stimulation of IP formation.
References:  7
Measurement of AC activity in baculovirus-infected Sf9 insect cells expressing the human H1 receptor.
Species:  Human
Tissue:  Sf9 cells.
Response measured:  Stimulation of AC activity.
References:  87
Measurement of cAMP levels in CHO cells transfected with the human H1 receptor.
Species:  Human
Tissue:  CHO cells.
Response measured:  Stimulation of cAMP accumulation.
References:  55
Measurement of PLC activity and Ca2+ mobilisation in cultured ciliary muscle cells endogenously expressing the H1 receptor.
Species:  Human
Tissue:  Cultured ciliary muscle cells.
Response measured:  Activation of PLC and mobilisation of both intracellular and extracellular Ca2+.
References:  53
Measurement of IP levels in cultured human endothelial cells endogenously expressing the H1 receptor.
Species:  Human
Tissue:  Cultured umbilical vein endothelial cells.
Response measured:  Stimulation of IP formation.
References:  50
Measurement of mitogenesis in human astrocytoma U373 MG cells endogenously expressing the H1 receptor.
Species:  Human
Tissue:  Astrocytoma U373 MG cells.
Response measured:  Cell proliferation via PKC and MAPK.
References:  32
Measurement of Ca2+ levels as well as ERK1/2 and PKC activity in human primary epithelial cells and the NCI-H292 cell line, both endogenously expressing the H1 receptor.
Species:  Human
Tissue:  Primary epithelial cells and the NCI-H292 cell line.
Response measured:  Elevation of Ca2+ levels and activation of PKC and ERK1/2.
References:  58
Measurement of IP, DAG and Ca2+ levels in human HeLa carcinoma cells endogenously expressing the H1 receptor.
Species:  Human
Tissue:  HeLa carcinoma cells.
Response measured:  Formation of IP and DAG and a rise in Ca2+ levels.
References:  83
Physiological Functions
Contraction of smooth muscle.
Species:  Rat
Tissue:  Isolated stomach fundus.
References:  17
Relaxation of smooth muscle (via an endothelial H1 receptor).
Species:  Human
Tissue:  Cranial arteries.
References:  39
Contraction of smooth muscle.
Species:  Human
Tissue:  Arterial rings.
References:  13
Modulation of adrenergic neurotransmission.
Species:  Rat
Tissue:  Vas deferens.
References:  84
Bronchoconstriction.
Species:  Human
Tissue:  In vivo.
References:  10-11,16,51,68,82
Inhibition of locomotor behaviour.
Species:  Rat
Tissue:  In vivo.
References:  1
Modulation of feeding behaviour.
Species:  Rat
Tissue:  In vivo.
References:  22
Modulation of feeding behaviour.
Species:  Mouse
Tissue:  In vivo.
References:  56-57,66-67
Hypernociception.
Species:  Rat
Tissue:  In vivo.
References:  52
Endothelium-dependent vasodilation.
Species:  Rat
Tissue:  Mesenteric vascular beds.
References:  41
Role in the stimulation of skin blood flow during whole body heating.
Species:  Human
Tissue:  In vivo.
References:  86
Stimulation of the nitric oxide signalling system.
Species:  Rat
Tissue:  Submandibular gland.
References:  8
Increased vascular permeability.
Species:  Mouse
Tissue:  In vivo.
References:  6,69
Modulation of neuronal firing.
Species:  Rat
Tissue:  Dorsal raphe nucleus.
References:  9
Contraction of smooth muscle.
Species:  Human
Tissue:  Isolated uterine strips.
References:  54
Increase in substantia nigra pars reticulata (SNr) inhibitory projection neuron firing frequency (via cell depolarisation).
The balance between the effect of H1 and H2 receptors and the opposing effect of H3 receptors may contribute to movement control.
Species:  Mouse
Tissue:  Coronal midbrain slices.
References:  90
Depolarisation.
Species:  Rat
Tissue:  Sympathetic preganglionic neurons.
References:  85
Regulation of cytokine production.
Species:  Mouse
Tissue:  CD4+ and CD8+ T cells.
References:  80
Prostacyclin formation.
Species:  Human
Tissue:  Pulmonary artery.
References:  76
Physiological Consequences of Altering Gene Expression
H1 receptor knockout mice develop normally, but exhibit impaired locomotor activity and exploratory behavior.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  36,89
H1 receptor knockout mice subjected to social isolation after weaning exhibit similar levels of locomotor activity to socially reared H1 receptor knockout mice. This is in contrast to wild-type mice, where there is a significant decrease in locomotor activity in socially isolated WT mice compared with socially reared WT mice. It is suggested that blockade of H1 receptors by atypical antipsychotics attenuates social isolation-induced behavioral changes.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  12
H1 receptor knockout mice exhibit decreased exploratory activity, reduced levels of anxiety and aggression, a decrease in nociceptive response and an increased 5-HT turnover rate in the cerebral cortex and hippocampus.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  88
H1 receptor knockout mice exhibit a significant decrease in nociception compared to wild-type mice.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  62
H1 knockout mice exhibit enhancement of morphine-induced antinociception.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  61
H1 receptor knockout mice do not exhibit an increase in respiratory frequency upon elevation of body temperature, as observed in wild-type mice.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  38
H1 receptor knockout mice exhibit a reduction in the effect of neurotensin on the supression of food intake.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  70
H1 receptor knockout mice do not exhibit an increase in vascular permeability of the conjunctiva, as observed in wild-type mice.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  69
CD4+ T cells from H1 receptor knockout mice exhibit a decrease in the release of Il-2 and Il-10, and an increase in the release of IL-4. CD8+ T cells from H1 receptor knockout mice also exhibit a decrease in the release of Il-2 and Il-10, as well as an increase in the release of IFN-γ.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  80
H1 receptor knockout mice exhibit enhanced antinociception by administration of orexin-A, compared to wild-type mice following administration of orexin-A.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  63
Phenotypes, Alleles and Disease Models Mouse data from MGI

Show »

Allele Composition & genetic background Accession Phenotype Id Phenotype Reference
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
involves: 129P2/OlaHsd * C57BL/6
MGI:107619  MP:0004924 abnormal behavior PMID: 8917588 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
involves: 129P2/OlaHsd * C57BL/6
MGI:107619  MP:0001502 abnormal circadian rhythm PMID: 8917588 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
B6.129P2-Hrh1
MGI:107619  MP:0003638 abnormal response/metabolism to endogenous compounds PMID: 15331534 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
involves: 129P2/OlaHsd * C57BL/6
MGI:107619  MP:0005093 decreased B cell proliferation PMID: 9989982 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
B6.129P2-Hrh1
MGI:107619  MP:0001262 decreased body weight PMID: 15331534 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
B6.129P2-Hrh1
MGI:107619  MP:0002727 decreased circulating insulin level PMID: 15331534 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
B6.129P2-Hrh1
MGI:107619  MP:0003910 decreased eating behavior PMID: 15331534 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
involves: 129P2/OlaHsd * C57BL/6
MGI:107619  MP:0001417 decreased exploration in new environment PMID: 8917588 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
involves: 129P2/OlaHsd * C57BL/6
MGI:107619  MP:0008498 decreased IgG3 level PMID: 9989982 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
involves: 129P2/OlaHsd * C57BL/6
MGI:107619  MP:0001806 decreased IgM level PMID: 9989982 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
B6.129P2-Hrh1
MGI:107619  MP:0001876 decreased inflammatory response PMID: 16680192 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
involves: 129P2/OlaHsd * C57BL/6
MGI:107619  MP:0008567 decreased interferon-gamma secretion PMID: 9989982 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
B6.129P2-Hrh1
MGI:107619  MP:0008567 decreased interferon-gamma secretion PMID: 16680192 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
B6.129P2-Hrh1
MGI:107619  MP:0008673 decreased interleukin-13 secretion PMID: 16680192 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
involves: 129P2/OlaHsd * C57BL/6
MGI:107619  MP:0008688 decreased interleukin-2 secretion PMID: 9989982 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
B6.129P2-Hrh1
MGI:107619  MP:0008703 decreased interleukin-5 secretion PMID: 16680192 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
involves: 129P2/OlaHsd * C57BL/6
MGI:107619  MP:0005018 decreased T cell number PMID: 9989982 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
involves: 129P2/OlaHsd * C57BL/6
MGI:107619  MP:0005095 decreased T cell proliferation PMID: 9989982 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
B6.129P2-Hrh1
MGI:107619  MP:0010025 decreased total body fat amount PMID: 15331534 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
involves: 129P2/OlaHsd * C57BL/6
MGI:107619  MP:0002757 decreased vertical activity PMID: 8917588 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
B6.129P2-Hrh1
MGI:107619  MP:0001260 increased body weight PMID: 15331534 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
B6.129P2-Hrh1
MGI:107619  MP:0000005 increased brown adipose tissue amount PMID: 15331534 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
B6.129P2-Hrh1
MGI:107619  MP:0001554 increased circulating free fatty acid level PMID: 15331534 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
B6.129P2-Hrh1
MGI:107619  MP:0005669 increased circulating leptin level PMID: 15331534 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
B6.129P2-Hrh1
MGI:107619  MP:0003909 increased eating behavior PMID: 15331534 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
B6.129P2-Hrh1
MGI:107619  MP:0006094 increased fat cell size PMID: 15331534 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
B6.129P2-Hrh1
MGI:107619  MP:0002493 increased IgG level PMID: 16680192 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
B6.129P2-Hrh1
MGI:107619  MP:0002494 increased IgM level PMID: 16680192 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
involves: 129P2/OlaHsd * C57BL/6
MGI:107619  MP:0008699 increased interleukin-4 secretion PMID: 9989982 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
B6.129P2-Hrh1
MGI:107619  MP:0009355 increased liver triglyceride level PMID: 15331534 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
B6.129P2-Hrh1
MGI:107619  MP:0005317 increased triglyceride level PMID: 15331534 
Hrh1tm1Wtn Hrh1tm1Wtn/Hrh1tm1Wtn
B6.129P2-Hrh1
MGI:107619  MP:0000008 increased white adipose tissue amount PMID: 15331534 

References

Show »

1. Alvarez EO, Banzán AM. (1986) Histamine in dorsal and ventral hippocampus. II. Effects of H1 and H2 histamine antagonists on exploratory behavior in male rats. Physiol Behav, 37: 39-45. [PMID:3016772]

2. Aslanian R, Piwinski JJ, Zhu X, Priestley T, Sorota S, Du XY, Zhang XS, McLeod RL, West RE, Williams SM et al.. (2009) Structural determinants for histamine H(1) affinity, hERG affinity and QTc prolongation in a series of terfenadine analogs. Bioorg. Med. Chem. Lett., 19 (17): 5043-7. [PMID:19660947]

3. Auerbach SS, DrugMatrix® and ToxFX® Coordinator National Toxicology Program. National Toxicology Program: Dept of Health and Human Services. Accessed on 02/05/2014. Modified on 02/05/2014. DrugMatrix, https://ntp.niehs.nih.gov/drugmatrix/index.html

4. Azuma H, Sawada S, Takeuchi S, Higashiyama K, Kakigi A, Takeda T. (2003) Expression of mRNA encoding the H1, H2, and H3 histamine receptors in the rat cochlea. Neuroreport, 14: 423-425. [PMID:12634496]

5. Bahl A, Barton P, Bowers K, Brough S, Evans R, Luckhurst CA, Mochel T, Perry MW, Rigby A, Riley RJ et al.. (2012) The discovery of CCR3/H1 dual antagonists with reduced hERG risk. Bioorg. Med. Chem. Lett., 22 (21): 6688-93. [PMID:23031591]

6. Bhargava KP, Nath R, Palit G. (1977) Nature of histamine receptors concerned in capillary permeability. Br J Pharmacol, 59: 349-351. [PMID:837022]

7. Booth RG, Moniri NH, Bakker RA, Choksi NY, Nix WB, Timmerman H, Leurs R. (2002) A novel phenylaminotetralin radioligand reveals a subpopulation of histamine H(1) receptors. J Pharmacol Exp Ther, 302: 328-336. [PMID:12065734]

8. Borda E, Stranieri G, Sterin-Borda L. (2002) H(1)-Receptor activation triggers the endogenous nitric oxide signalling system in the rat submandibular gland. Mediators Inflamm, 11: 337-343. [PMID:12581497]

9. Bárbara A, Aceves J, Arias-Montaño JA. (2002) Histamine H1 receptors in rat dorsal raphe nucleus: pharmacological characterisation and linking to increased neuronal activity. Brain Res, 954: 247-255. [PMID:12414108]

10. Casterline CL, Evans R. (1977) Further studies on the mechanism of human histamine-induced asthma: the effect of an aerosolized H1 receptor antagonist (diphenhydramine). J Allergy Clin Immunol, 59: 420-424. [PMID:16944]

11. Crimi N, Polosa R, Magrì S, Prosperini G, Paolino G, Mastruzzo C, Mistretta A. (1996) Inhaled lysine acetylsalicylate (L-ASA) attenuates histamine-induced bronchoconstriction in asthma. Allergy, 51: 157-163. [PMID:8781669]

12. Dai H, Okuda T, Sakurai E, Kuramasu A, Kato M, Jia F, Xu AJ, Iinuma K, Sato I, Yanai K. (2005) Blockage of histamine H1 receptor attenuates social isolation-induced disruption of prepulse inhibition: a study in H1 receptor gene knockout mice. Psychopharmacology (Berl), 183: 285-293. [PMID:16237577]

13. Daneshmand MA, Keller RS, Canver MC, Canver AC, Canver CC. (2004) Histamine H1 and H2 receptor-mediated vasoreactivity of human internal thoracic and radial arteries. Surgery, 136: 458-463. [PMID:15300215]

14. De Backer MD, Gommeren W, Moereels H, Nobels G, Van Gompel P, Leysen JE, Luyten WH. (1993) Genomic cloning, heterologous expression and pharmacological characterization of a human histamine H1 receptor. Biochem Biophys Res Commun, 197: 1601-1608. [PMID:8280179]

15. De Backer MD, Loonen I, Verhasselt P, Neefs JM, Luyten WH. (1998) Structure of the human histamine H1 receptor gene. Biochem J, 335: 663-670. [PMID:9794809]

16. Eiser NM, Mills J, Snashall PD, Guz A. (1981) The role of histamine receptors in asthma. Clin Sci (Lond), 60: 363-370. [PMID:7249528]

17. Ercan ZS, Türker RK. (1977) Histamine receptors in the isolated rat stomach fundus and rabbit aortic strips. Pharmacology, 15: 118-126. [PMID:847009]

18. Esbenshade TA, Fox GB, Krueger KM, Baranowski JL, Miller TR, Kang CH, Denny LI, Witte DG, Yao BB, Pan JB, Faghih R, Bennani YL, Williams M, Hancock AA. (2004) Pharmacological and behavioral properties of A-349821, a selective and potent human histamine H3 receptor antagonist. Biochem Pharmacol, 68: 933-945. [PMID:15294456]

19. Esbenshade TA, Fox GB, Krueger KM, Miller TR, Kang CH, Denny LI, Witte DG, Yao BB, Pan L, Wetter J, Marsh K, Bennani YL, Cowart MD, Sullivan JP, Hancock AA. (2005) Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: I. Potent and selective histamine H3 receptor antagonist with drug-like properties. J Pharmacol Exp Ther, 313: 165-175. [PMID:15608078]

20. Esbenshade TA, Krueger KM, Miller TR, Kang CH, Denny LI, Witte DG, Yao BB, Fox GB, Faghih R, Bennani YL, Williams M, Hancock AA. (2003) Two novel and selective nonimidazole histamine H3 receptor antagonists A-304121 and A-317920: I. In vitro pharmacological effects. J Pharmacol Exp Ther, 305: 887-896. [PMID:12606603]

21. Fujimoto K, Horio Y, Sugama K, Ito S, Liu YQ, Fukui H. (1993) Genomic cloning of the rat histamine H1 receptor. Biochem Biophys Res Commun, 190: 294-301. [PMID:7678492]

22. Fukagawa K, Sakata T, Shiraishi T, Yoshimatsu H, Fujimoto K, Ookuma K, Wada H. (1989) Neuronal histamine modulates feeding behavior through H1-receptor in rat hypothalamus. Am J Physiol, 256: R605-R611. [PMID:2564258]

23. Fukui H, Fujimoto K, Mizuguchi H, Sakamoto K, Horio Y, Takai S, Yamada K, Ito S. (1994) Molecular cloning of the human H1-receptor gene. Biochem. Biophys. Res. Commun., 201: 894-901. [PMID:8003029]

24. Gangwar RS, Landolina N, Arpinati L, Levi-Schaffer F. (2017) Mast cell and eosinophil surface receptors as targets for anti-allergic therapy. Pharmacol. Ther., 170: 37-63. [PMID:27773785]

25. Ghoneim OM, Legere JA, Golbraikh A, Tropsha A, Booth RG. (2006) Novel ligands for the human histamine H1 receptor: synthesis, pharmacology, and comparative molecular field analysis studies of 2-dimethylamino-5-(6)-phenyl-1,2,3,4-tetrahydronaphthalenes. Bioorg. Med. Chem., 14 (19): 6640-58. [PMID:16782354]

26. Gibbs BF, Levi-Schaffer F. (2012) H₄ receptors in mast cells and basophils: a new therapeutic target for allergy?. Front Biosci (Landmark Ed), 17: 430-7. [PMID:22201753]

27. Gillard M, Van Der Perren C, Moguilevsky N, Massingham R, Chatelain P. (2002) Binding characteristics of cetirizine and levocetirizine to human H(1) histamine receptors: contribution of Lys(191) and Thr(194). Mol. Pharmacol., 61 (2): 391-9. [PMID:11809864]

28. Gonzalez R, Echeverria E, Reinicke K, Rudolph MI. (1994) Increased affinity of histamine H1 binding to membranes of human myometrium at the end of pregnancy. Gen Pharmacol, 25: 1607-1610. [PMID:7721035]

29. Gonzalez R, Reinicke K, Rudolph GM. (1993) Histamine H1 receptor binding sites in mouse uterine horns. Gen Pharmacol, 24: 29-33. [PMID:8482504]

30. Govoni M, Bakker RA, van de Wetering I, Smit MJ, Menge WM, Timmerman H, Elz S, Schunack W, Leurs R. (2003) Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists. J. Med. Chem., 46 (26): 5812-24. [PMID:14667234]

31. Heinrich T, Böttcher H, Gericke R, Bartoszyk GD, Anzali S, Seyfried CA, Greiner HE, Van Amsterdam C. (2004) Synthesis and structure--activity relationship in a class of indolebutylpiperazines as dual 5-HT(1A) receptor agonists and serotonin reuptake inhibitors. J. Med. Chem., 47 (19): 4684-92. [PMID:15341484]

32. Hernández-Angeles A, Soria-Jasso LE, Ortega A, Arias-Montaño JA. (2001) Histamine H1 receptor activation stimulates mitogenesis in human astrocytoma U373 MG cells. J Neurooncol, 55: 81-89. [PMID:11817705]

33. Hishinuma S, Sato Y, Kobayashi Y, Komazaki H, Saito M. (2008) Intact cell binding for in vitro prediction of sedative and non-sedative histamine H1-receptor antagonists based on receptor internalization. J. Pharmacol. Sci., 107 (1): 66-79. [PMID:18446005]

34. Hofstra CL, Desai PJ, Thurmond RL, Fung-Leung WP. (2003) Histamine H4 receptor mediates chemotaxis and calcium mobilization of mast cells. J Pharmacol Exp Ther, 305: 1212-1221. [PMID:12626656]

35. Inoue I, Taniuchi I, Kitamura D, Jenkins NA, Gilbert DJ, Copeland NG, Watanabe T. (1996) Characteristics of the mouse genomic histamine H1 receptor gene. Genomics, 36: 178-181. [PMID:8812432]

36. Inoue I, Yanai K, Kitamura D, Taniuchi I, Kobayashi T, Niimura K, Watanabe T, Watanabe T. (1996) Impaired locomotor activity and exploratory behavior in mice lacking histamine H1 receptors. Proc Natl Acad Sci U S A, 93: 13316-13320. [PMID:8917588]

37. Ishiwata K, Kawamura K, Wang WF, Tsukada H, Harada N, Mochizuki H, Kimura Y, Ishii K, Iwata R, Yanai K. (2004) Evaluation of in vivo selective binding of [11C]doxepin to histamine H1 receptors in five animal species. Nucl. Med. Biol., 31 (4): 493-502. [PMID:15093820]

38. Izumizaki M, Iwase M, Kimura H, Yanai K, Watanabe T, Homma I. (2000) Lack of temperature-induced polypnea in histamine H1 receptor-deficient mice. Neurosci Lett, 284: 139-142. [PMID:10773418]

39. Jansen-Olesen I, Ottosson A, Cantera L, Strunk S, Lassen LH, Olesen J, Mortensen A, Engel U, Edvinsson L. (1997) Role of endothelium and nitric oxide in histamine-induced responses in human cranial arteries and detection of mRNA encoding H1- and H2-receptors by RT-PCR. Br J Pharmacol, 121: 41-48. [PMID:9146885]

40. Janssens F, Leenaerts J, Diels G, De Boeck B, Megens A, Langlois X, van Rossem K, Beetens J, Borgers M. (2005) Norpiperidine imidazoazepines as a new class of potent, selective, and nonsedative H1 antihistamines. J. Med. Chem., 48 (6): 2154-66. [PMID:15771458]